Savara Short Term Debt Over Time
| SVRA Stock | USD 2.49 0.03 1.22% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Savara Performance and Savara Correlation. Savara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Savara. If investors know Savara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Savara listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Savara Inc is measured differently than its book value, which is the value of Savara that is recorded on the company's balance sheet. Investors also form their own opinion of Savara's value that differs from its market value or its book value, called intrinsic value, which is Savara's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Savara's market value can be influenced by many factors that don't directly affect Savara's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Savara's value and its price as these two are different measures arrived at by different means. Investors typically determine if Savara is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Savara's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Term Debt Analysis
Compare Savara Inc and related stocks such as Stoke Therapeutics, Edgewise Therapeutics, and Crinetics Pharmaceuticals Short Term Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOK | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 M | 1.1 M | 1.5 M | 2.4 M | 2.4 M | 2.7 M | 2.9 M |
| EWTX | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 980 K | 882 K | 878.4 K |
| CRNX | 49 K | 49 K | 49 K | 49 K | 49 K | 49 K | 49 K | 724 K | 724 K | 724 K | 835 K | 939 K | 1.1 M | 4.2 M | 4.8 M | 5 M |
| DYN | 51 M | 4 M | 29 M | 13 M | 31 M | 83 M | 201 M | 105 M | 7.8 M | 7.8 M | 7.8 M | 7.8 M | 9.2 M | 4.7 M | 4.8 M | 4.6 M |
| RVMD | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 172 K | 3.7 M | 12.4 M | 13.5 M | 7.4 M | 12.9 M | 7.9 M |
| IKNA | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | (17.6 M) | 3.7 M | 3.8 M | 3.6 M | 4.1 M | 4.3 M |
| XLO | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 801 K | 7.6 M | 3.3 M | 3.8 M | 4 M |
| TARA | 176 K | 176 K | 176 K | 176 K | 176 K | 176 K | 176 K | 176 K | 176 K | 176 K | 176 K | 1.7 M | 1.8 M | 983 K | 1.1 M | 1.3 M |
| SRRK | 647 K | 647 K | 647 K | 647 K | 647 K | 647 K | 647 K | 641 K | 438 K | 1.1 M | 10.7 M | 16.4 M | 15.7 M | 8.7 M | 10.1 M | 7.5 M |
| FENC | 25.6 K | 2.9 M | 2.9 M | 2.9 M | 1.3 M | 82 K | 33 K | 167 K | 12 K | 12 K | 12 K | 12 K | 21 K | 21 K | 18.9 K | 18 K |
| XOMA | 100 K | 10.4 M | 3.4 M | 5.8 M | 19.2 M | 5.9 M | 17.9 M | 3.4 M | 789 K | 5.3 M | 8.3 M | 390 K | 68 K | 5.6 M | 6.4 M | 4.7 M |
| KZR | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 2.1 M | 2.4 M | 5.1 M | 3 M | 3.5 M | 3 M |
| TRDA | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 14.9 M | 7.6 M | 10.5 M |
| ANAB | 932 K | 932 K | 932 K | 932 K | 129 K | 21 K | 1000 | 6.9 M | 7.6 M | 2.2 M | 342 K | 3 M | 3.3 M | 1.8 M | 2 M | 2.6 M |
| ACLX | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 100 K | 36 M | 47.8 M | 54.9 M | 30.7 M |
| GPCR | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 147 K | 349 K | 520 K | 1.4 M | 1.7 M | 1.7 M |
| AVTE | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 770 K | 420 K | 483 K | 577.1 K |
| ALXO | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 742 K | 1 M | 1.6 M | 1.8 M | 1.2 M |
| RZLT | 3.7 M | 3.7 M | 3.7 M | 60 K | 153.9 K | 83.1 K | 10 K | 3.4 M | 10 K | 245 K | 530 K | 108 K | 541 K | 568 K | 511.2 K | 631.7 K |
| PTIX | 2 M | 2.6 M | 2.6 M | 0.0 | 0.0 | 399 | 0.0 | 0.0 | 0.0 | 186.1 K | 186.1 K | 186.1 K | 344.2 K | 344.2 K | 309.8 K | 294.3 K |
| TPST | 189 K | 189 K | 189 K | 189 K | 189 K | 189 K | 189 K | 189 K | 189 K | 2 M | 712 K | 2.9 M | 2.8 M | 5.2 M | 6 M | 6.3 M |
Savara Inc and related stocks such as Stoke Therapeutics, Edgewise Therapeutics, and Crinetics Pharmaceuticals Short Term Debt description
My Equities
My Current Equities and Potential Positions
| Savara Inc | SVRA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.37
Check out Savara Performance and Savara Correlation. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Savara technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.